#ES­MO22: Am­gen drops the de­tailed deck for KRAS G12C, with erod­ing da­ta like­ly to trig­ger fresh de­bate

PARIS — Am­gen put its best foot for­ward in Paris ear­ly Mon­day, with the news that its KRAS G12C star Lumakras of­fered a sol­id ben­e­fit for pa­tients suf­fer­ing from ad­vanced cas­es of non-small cell lung can­cer com­pared with chemo. The top-line fig­ures in­clud­ed a drop of 34% in the risk of dis­ease pro­gres­sion at 12 months in Code­BreaK 200, the con­fir­ma­to­ry study be­ing used for a near cer­tain full ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER